125 related articles for article (PubMed ID: 2398547)
1. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.
Keane TE; Rosner G; Donaldson JT; Norwood DL; Poulton SH; Walther PJ
J Urol; 1990 Oct; 144(4):1004-9. PubMed ID: 2398547
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
Keane TE; Rosner GL; Gingrich JR; Poulton SH; Walther PJ
J Urol; 1991 Nov; 146(5):1418-24. PubMed ID: 1942313
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammineplatinum-induced cytotoxicity in mouse xenograft model of bladder cancer.
Kosugi M; Miyajima A; Kikuchi E; Kosaka T; Horiguchi Y; Murai M; Oya M
Urology; 2009 Mar; 73(3):655-60. PubMed ID: 19167032
[TBL] [Abstract][Full Text] [Related]
4. [Non-cross-resistant sequential combination chemotherapy consisting of cis-diammine-dichloroplatinum (II) mainly, based on synchronization theory, in human bladder cancer xenografts in athymic nude mice].
Yamauchi T; Okada K; Yoshida O
Hinyokika Kiyo; 1986 Dec; 32(12):1781-97. PubMed ID: 2435129
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
6. Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts.
Hida S; Okada K; Yoshida O
Jpn J Cancer Res; 1990 Apr; 81(4):425-30. PubMed ID: 2114395
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of CDDP and VP-16 against human bladder cancers.
Gotoh A; Mizuno Y; Okada H; Arakawa S; Kitazawa S; Maeda S; Kamidono S
In Vivo; 1995; 9(3):263-7. PubMed ID: 8562894
[TBL] [Abstract][Full Text] [Related]
8. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
9. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
11. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model.
Keane TE; Gingrich JR; Rosner G; Webb KS; Poulton SH; Walther PJ
Cancer Res; 1994 Jan; 54(2):475-81. PubMed ID: 8275484
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
13. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
Yamauchi T; Hida S; Ooishi K; Okada K; Yoshida O
Hinyokika Kiyo; 1985 Jul; 31(7):1093-104. PubMed ID: 2414981
[TBL] [Abstract][Full Text] [Related]
14. [Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts].
Miki T; Kotake T
Hinyokika Kiyo; 1993 Dec; 39(12):1221-5. PubMed ID: 8285173
[TBL] [Abstract][Full Text] [Related]
15. [Neoadjuvant chemotherapy using cisplatin (CDDP) and methotrexate (MTX) in carcinoma of the bladder].
Rocco F; Scardino E; Strada G; Franchini V; Larcher P; Favini P; Baccalin A; Giuberti A; Criscpino S; Tancini G
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):249-55. PubMed ID: 2142809
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B.
Cao SS; Zhen YS
Cancer Chemother Pharmacol; 1989; 24(3):181-6. PubMed ID: 2736709
[TBL] [Abstract][Full Text] [Related]
17. Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
Barberi-Heyob M; Griffon G; Merlin JL; Weber B
Cancer Chemother Pharmacol; 1993; 33(2):163-70. PubMed ID: 8261577
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system.
Keane TE; El-Galley RE; Sun C; Petros JA; Dillahey D; Gomaa A; Graham SD; McGuire WP
J Urol; 1998 Jul; 160(1):252-6. PubMed ID: 9628659
[TBL] [Abstract][Full Text] [Related]
19. Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.
Ogihara K; Kikuchi E; Okazaki S; Hagiwara M; Takeda T; Matsumoto K; Kosaka T; Mikami S; Saya H; Oya M
Cancer Sci; 2019 Apr; 110(4):1431-1441. PubMed ID: 30719824
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of neoadjuvant intraarterial chemotherapy (I A-MAC) for advanced bladder cancer].
Takahashi Y; Deguchi T; Kuriyama M; Nakano M; Ueno K; Shinoda I; Takeda A; Itoh S; Doi T; Takeuchi T
Gan To Kagaku Ryoho; 1994 Sep; 21(13):2311-4. PubMed ID: 7944467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
